1
|
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. Int J Urol 2024; 31:526-533. [PMID: 38240169 DOI: 10.1111/iju.15396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 01/04/2024] [Indexed: 05/05/2024]
Abstract
OBJECTIVES This study aimed to assess the prognostic outcomes in mRCC patients receiving second-line TKI following first-line IO combination therapy. METHODS This study retrospectively included 243 mRCC patients receiving second-line TKI after first-line IO combination therapy: nivolumab plus ipilimumab (n = 189, IO-IO group) and either pembrolizumab plus axitinib or avelumab plus axitinib (n = 54, IO-TKI group). Oncological outcomes between the two groups were compared, and prognostication systems were developed for these patients. RESULTS In the IO-IO and IO-TKI groups, the objective response rates to second-line TKI were 34.4% and 25.9% (p = 0.26), the median PFS periods were 9.7 and 7.1 months (p = 0.79), and the median OS periods after the introduction of second-line TKI were 23.1 and 33.5 months (p = 0.93), respectively. Among the several factors examined, non-CCRCC, high CRP, and low albumin levels were identified as independent predictors of both poor PFS and OS by multivariate analyses. It was possible to precisely classify the patients into 3 risk groups regarding both PFS and OS according to the positive numbers of the independent prognostic factors. Furthermore, the c-indices of this study were superior to those of previous systems as follows: 0.75, 0.64, and 0.61 for PFS prediction and 0.76, 0.70, and 0.65 for OS prediction by the present, IMDC, and MSKCC systems, respectively. CONCLUSIONS There were no significant differences in the prognostic outcomes after introducing second-line TKI between the IO-IO and IO-TKI groups, and the histopathology, CRP and albumin levels had independent impacts on the prognosis in mRCC patients receiving second-line TKI, irrespective of first-line IO combination therapies.
Collapse
Affiliation(s)
- Yuto Matsushita
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Takahiro Kojima
- Department of Urology, Aichi Cancer Center, Nagoya, Aichi, Japan
| | - Takahiro Osawa
- Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Hokkaido, Japan
| | - Tomokazu Sazuka
- Department of Urology, Graduate School of Medicine and School of Medicine, Chiba University, Chiba, Chiba, Japan
| | - Shingo Hatakeyama
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan
| | - Keisuke Goto
- Department of Urology, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Hiroshima, Japan
| | - Kazuyuki Numakura
- Department of Urology, Akita University Graduate School of Medicine, Akita, Akita, Japan
| | - Kazutoshi Yamana
- Department of Urology and Molecular Oncology, Niigata University Graduate school of medical and dental sciences, Niigata, Niigata, Japan
| | - Shuya Kandori
- Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
| | - Kazutoshi Fujita
- Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan
| | - Kosuke Ueda
- Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
| | - Hajime Tanaka
- Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Ryotaro Tomida
- Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Tokushima, Japan
| | - Toshifumi Kurahashi
- Department of Urology, Hyogo Prefectural Cancer Center, Akashi, Hyogo, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Naotaka Nishiyama
- Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan
| | - Takahiro Kimura
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
| | - Shimpei Yamashita
- Department of Urology, Wakayama Medical University, Wakayama, Wakayama, Japan
| | - Hiroshi Kitamura
- Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Toyama, Japan
| | - Hideaki Miyake
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| |
Collapse
|
2
|
Nishimoto H, Inui A, Mifune Y, Yamaura K, Bando Y, Okamura Y, Hara T, Terakawa T, Kuroda R. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan. Medicina (Kaunas) 2024; 60:551. [PMID: 38674197 PMCID: PMC11052390 DOI: 10.3390/medicina60040551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Revised: 03/05/2024] [Accepted: 03/26/2024] [Indexed: 04/28/2024]
Abstract
Background and Objectives: Androgen deprivation therapy (ADT) for prostate cancer has greatly improved treatment outcomes. As patient survival rates have increased, reports of decreased bone density and increased bone fractures as side effects of ADT have emerged. The prevalence of osteoporosis in Japanese men was 4.6%. The purpose of this study was to evaluate the effect of osteoporosis treatment in prostate cancer patients who underwent ADT in Japan. Materials and Methods: The subjects were 33 male patients who had undergone ADT for prostate cancer, who were noted to have decreased bone density. Mean age was 76.2 ± 7.7 years (64-87). Medications included vitamin D in one case, bisphosphonates (BP) in 27 cases, and denosumab in five cases. The evaluation method examined the rate of change in bone mineral density (BMD) before osteoporosis treatment and 1 year after. For comparison, a group without osteoporosis treatment intervention (n = 33) was selected, and matched for prostate cancer treatment and age. The rate of change in trabecular bone score (TBS) was also calculated. Results: The percentage changes in BMD before and 1 year after treatment were as follows: lumbar spine, 7.1 ± 5.8% in the treatment group versus -3.9 ± 4.1% in the no treatment group; femoral neck, 5.5 ± 6.2% in the treatment group versus -0.9 ± 3.9% in the no treatment group; total femur, 6.6 ± 6.4% in the treatment group versus the no treatment group which was -1.7 ± 3.2%. In all cases, there was a clear significant difference (p < 0.01). The percent change in TBS was further calculated in the same manner. There was no significant difference between the two groups: +1.7 ± 3.8% in the treated group versus +0.3 ± 4.1% in the untreated group. Conclusions: Osteoporosis treatment in Japanese patients with prostate cancer on ADT therapy was found to significantly increase BMD compared to the untreated group. BP and denosumab were found to be very effective in increasing BMD.
Collapse
Affiliation(s)
- Hanako Nishimoto
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (H.N.); (Y.M.); (R.K.)
| | - Atsuyuki Inui
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (H.N.); (Y.M.); (R.K.)
| | - Yutaka Mifune
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (H.N.); (Y.M.); (R.K.)
| | - Kohei Yamaura
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (H.N.); (Y.M.); (R.K.)
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (Y.B.); (Y.O.); (T.H.)
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (Y.B.); (Y.O.); (T.H.)
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (Y.B.); (Y.O.); (T.H.)
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (Y.B.); (Y.O.); (T.H.)
| | - Ryosuke Kuroda
- Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; (H.N.); (Y.M.); (R.K.)
| |
Collapse
|
3
|
Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma. Can Urol Assoc J 2024; 18:cuaj.8548. [PMID: 38319607 DOI: 10.5489/cuaj.8548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
Abstract
INTRODUCTION We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for metastatic non-clear-cell renal cell carcinoma (nccRCC). METHODS We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared. RESULTS The first-line regimens was ICI-ICI regimens in 26 cases and ICI-TKI regimens in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between them (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535) nor above grade 3 (p=0.3786) between the ICI-ICI and ICITKI groups. CONCLUSIONS From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.
Collapse
Affiliation(s)
- Jun Teishima
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Taisuke Tobe
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Junichiro Hirata
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Hideto Ueki
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Naoto Wakita
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Yusuke Shiraishi
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yuzo Nakano
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
4
|
Ueki H, Terakawa T, Okamura Y, Bando Y, Hara T, Furukawa J, Nakano Y, Fujisawa M. Robot-assisted laparoscopic pyeloplasty in the management of lower pole ureteropelvic junction obstruction in a patient with an incomplete duplicated collecting system. IJU Case Rep 2023; 6:357-361. [PMID: 37928291 PMCID: PMC10622220 DOI: 10.1002/iju5.12622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Accepted: 07/31/2023] [Indexed: 11/07/2023] Open
Abstract
Introduction The performance of robot-assisted laparoscopic pyeloplasty has recently been increasing in frequency. However, patients with duplicated renal pelvises and ureters can present challenges. Case presentation A 71-year-old woman presented with flank pain and was diagnosed with ureteropelvic junction obstruction with an incomplete duplicated collecting system. Preoperative imaging did not reveal the details of the stenosis. Therefore, three reconstructive procedures were prepared: The Anderson-Hynes procedure, end-to-side pyeloureterostomy, and upper pole ureter to lower pole pyeloplasty with the Anderson-Hynes procedure for the lower pole. These procedures were determined by the length of the intact ureter and the presence of crossed vessels. During the surgery, the crossing vein was severed, allowing successful reconstruction with Anderson-Hynes anastomosis. Conclusion Preoperative evaluation and preparation of multiple surgical techniques are crucial in robot-assisted laparoscopic pyeloplasty for incomplete duplicated collecting systems.
Collapse
Affiliation(s)
- Hideto Ueki
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Tomoaki Terakawa
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Yasuyoshi Okamura
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Yukari Bando
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Takuto Hara
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Junya Furukawa
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Yuzo Nakano
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| | - Masato Fujisawa
- Department of Urology Kobe University Graduate School of Medicine Kobe Japan
| |
Collapse
|
5
|
Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M. The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinoma. Oncol Lett 2023; 26:470. [PMID: 37809051 PMCID: PMC10551863 DOI: 10.3892/ol.2023.14057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 08/08/2023] [Indexed: 10/10/2023] Open
Abstract
The present study aimed to clarify the relationship between the therapeutic outcome of combination regimens, including immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs), and cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). The present study retrospectively assessed the association between treatment efficacy and prognosis with or without CN, and the timing of CN in 151 patients treated with combination regimens for mRCC who were categorized as intermediate/poor risk. The first-line regimens included the ICI-ICI and ICI-TKI regimens in 98 and 53 cases, respectively. In patients with recurrence after radical surgery (n=66), the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 33.6 months and not reached (NR) (P=0.4032), respectively, and the 50% OS times were 53.7 months and NR (P=0.6886), respectively. Among the 38 patients with metastasis from the initial diagnosis who underwent upfront CN, the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 10.5 and 8.2 months (P=0.5806), respectively, and the 50% OS times were NR and 15.8 months (P=0.0587), respectively. Among the 51 patients who did not receive upfront CN, the 50% PFS time of the ICI-TKI group was significantly higher than that in the ICI-ICI group (4.1 months and NR, respectively; P=0.0210), and the 50% OS times were 29.8 months and NR (P=0.7343), respectively. In conclusion, according to the analysis of real-world data, good therapeutic efficacy can be achieved with any regimen in patients with recurrence after radical surgery. In addition, improved results could be achieved through treatment with ICI-TKI in patients without upfront CN.
Collapse
Affiliation(s)
- Jun Teishima
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Takuto Hara
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Taisuke Tobe
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Junichiro Hirata
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Hideto Ueki
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Naoto Wakita
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Yusuke Shiraishi
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Yasuyoshi Okamura
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Yukari Bando
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Tomoaki Terakawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Junya Furukawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Ken-Ichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807-8555, Japan
| | - Yuzo Nakano
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| | - Masato Fujisawa
- Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan
| |
Collapse
|
6
|
Tobe T, Terakawa T, Hara T, Ueki H, Shiraishi Y, Wakita N, Okamura Y, Bando Y, Furukawa J, Nakano Y, Harada K, Fujisawa M. The Efficacy of Presurgical Therapy With Avelumab and Axitinib for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer 2023; 21:613.e1-613.e6. [PMID: 37236863 DOI: 10.1016/j.clgc.2023.04.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 04/18/2023] [Accepted: 04/24/2023] [Indexed: 05/28/2023]
Affiliation(s)
- Taisuke Tobe
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Hideto Ueki
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yusuke Shiraishi
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Naoto Wakita
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Kenichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| |
Collapse
|
7
|
Harada KI, Sato R, Bando Y, Sano A, Matsushita Y, Tamura K, Terakawa T, Furukawa J, Fujimoto N, Fujisawa M, Miyake H. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan. Int J Urol 2023; 30:772-777. [PMID: 37345413 DOI: 10.1111/iju.15230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 06/04/2023] [Indexed: 06/23/2023]
Abstract
OBJECTIVES The objective of this study was to assess the clinical outcomes following combined treatment with pembrolizumab and axitinib as first-line therapy for patients with advanced RCC. METHODS This study retrospectively included 47 consecutive Japanese patients who were diagnosed with advanced RCC and subsequently received pembrolizumab and axitinib between February 2020 and January 2022. Efficacy and safety of this combined therapy in these patients were comprehensively investigated. RESULTS The 47 included patients were classified into the following 3 groups by the IMDC system: favorable, 7 (14.9%); intermediate, 24 (51.1%) and poor, 16 (34.0%). Responses to this combined therapy in the 47 patients were as follows: CR, 8 (17.0%); PR, 20 (42.6%); SD, 16 (34.0%) and PD, 3 (6.4%); thus, the ORR was 59.6%. During the observation period, disease progression and death occurred in 19 (40.4%) and 9 (19.1%) patients, respectively, and the median PFS and OS were 18 months and not reached, respectively. Univariate analyses identified the following significant predictors for poor prognostic outcomes: lack of nephrectomy, liver metastasis, bone metastasis, elevated CRP and IMDC poor risk for PFS; and lack of nephrectomy, non-CCC and elevated CRP for OS. AEs and those corresponding to grade ≥ 3 occurred in all (100%) and 30 (63.8%) patients, respectively. CONCLUSIONS To our knowledge, this is the first study focusing on real-world outcomes following pembrolizumab and axitinib for treatment-naïve advanced Japanese RCC patients, which showed the efficacy and safety of this combined therapy being similar or even superior to those in clinical trial.
Collapse
Affiliation(s)
- Ken-Ichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Ryo Sato
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yukari Bando
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Asuka Sano
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuto Matsushita
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Keita Tamura
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomoaki Terakawa
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Naohiro Fujimoto
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Masato Fujisawa
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hideaki Miyake
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
8
|
Hara T, Terakawa T, Okamura Y, Bando Y, Furukawa J, Harada K, Nakano Y, Fujisawa M. Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy. Prostate 2023; 83:1270-1278. [PMID: 37316357 DOI: 10.1002/pros.24588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 05/11/2023] [Accepted: 06/05/2023] [Indexed: 06/16/2023]
Abstract
BACKGROUND The objective of this study was to evaluate the background and treatment course of patients with metastatic prostate cancer (PC), with a particular focus on radiographic progression in the absence of prostate-specific antigen (PSA) progression. METHODS The study population consisted of 229 patients with metastatic hormone-sensitive PC (HSPC), who received prostate biopsy and androgen deprivation therapy at Kobe University Hospital between January 2008 and June 2022. Clinical characteristics were retrospectively evaluated using medical records. PSA progression-free status was defined as ≤1.05 times greater than that from 3 months before. Multivariate analyses were performed using the Cox proportional hazards regression model to identify parameters associated with time to progression on imaging without PSA elevation. RESULTS A total of 227 patients with metastatic HSPC without neuroendocrine PC were identified. The median follow-up period was 38.0 months, with a median overall survival of 94.9 months. Six patients exhibited disease progression on imaging without PSA elevation during HSPC treatment, three during first-line castration-resistant PC (CRPC) treatment, and two during late-line CRPC treatment. The rate of disease progression without PSA elevation at 3 years after treatment initiation was 7.4%. Multivariate analysis revealed that organ metastases and upfront treatment with docetaxel or androgen receptor axis-targeted therapy were independent prognostic factors for imaging progression without PSA elevation. CONCLUSIONS Disease progression on imaging without PSA elevation occurred not only during HSPC treatment and first-line CRPC treatment, but also during late-line CRPC treatment. Patients with visceral metastases or those treated with upfront androgen receptor axis-targeted or docetaxel may be more prone to such progression.
Collapse
Affiliation(s)
- Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
9
|
Hara T, Furukawa J, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Harada K, Nakano Y, Fujisawa M. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma. Int J Urol 2023; 30:746-752. [PMID: 37130778 DOI: 10.1111/iju.15193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Accepted: 04/11/2023] [Indexed: 05/04/2023]
Abstract
OBJECTIVES The efficacy of cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs) has been suggested in the real-world setting. We retrospectively examined the efficacy of CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC. METHODS Synchronous mRCC patients who received nivolumab plus ipilimumab at Kobe University Hospital or five affiliated hospitals between October 2018 and December 2021 were included in this study. We compared the outcomes of objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) between patients with CN prior to systemic therapy and without CN. In addition, patients were 1:1 matched by propensity scores accounting for factors associated with treatment assignment. RESULTS Twenty-one patients received CN prior to nivolumab plus ipilimumab (Prior CN) and 33 received nivolumab plus ipilimumab alone (Without CN). PFS of the Prior CN group was 10.8 months (95%CI 5.5-NR) and 3.4 months (95%CI 2.0-5.9) for the Without CN group (p = 0.0158). OS of Prior CN was 38.4 months (95%CI NR-NR) and 12.6 months (95%CI 4.2-30.8) for Without CN (p = 0.0024). Univariate and multivariate analyses identified prior CN as a significant prognostic indicator for PFS and OS. Moreover, propensity score matching analysis showed significant improvements in PFS and OS in Prior CN. CONCLUSIONS Patients who underwent CN prior to nivolumab plus ipilimumab systemic therapy for synchronous mRCC had a better prognosis than patients treated with nivolumab plus ipilimumab alone. These results suggest the efficacy of prior CN for synchronous mRCC with ICI combination therapy.
Collapse
Affiliation(s)
- Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yusuke Shiraishi
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
10
|
Hara T, Furukawa J, Okamura Y, Bando Y, Terakawa T, Harada K, Takahashi S, Nakano Y, Fujisawa M. The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion. Int J Urol 2023; 30:779-786. [PMID: 37317886 DOI: 10.1111/iju.15231] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 06/04/2023] [Indexed: 06/16/2023]
Abstract
OBJECTIVES We investigated poor prognosticators in advanced or unresectable urothelial carcinoma, focusing on renal parenchymal invasion (RPI). METHODS This study included 48 bladder cancer (BC) and 67 upper tract urothelial carcinoma (UTUC) patients treated with pembrolizumab from December 2017 to September 2022 at Kobe University Hospital. Medical records were retrospectively reviewed for clinical characteristics, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Multivariate analyses were performed using the Cox proportional hazard regression model to identify parameters associated with either PFS or OS. RESULTS Of 67 UTUC patients, 23 had RPI and 41 patients did not, while 3 cases could not be evaluated. Patients with RPI were predominantly elderly and had liver metastases. ORR for patients with RPI was 8.7%, while it was 19.5% for those without RPI. PFS was significantly shorter for patients with RPI compared with those without RPI. Patients with RPI had significantly shorter OS than those without RPI. On multivariate analysis, performance status (PS) ≥ 2, neutrophil-lymphocyte ratio (NLR) ≥ 3, C-reactive protein ≥0.3 mg/dL and RPI were independent prognostic factors for PFS. PS ≥ 2, NLR ≥ 3, visceral metastasis and RPI were independent prognostic factors for OS. UTUC patient OS was significantly shorter than BC patient OS, while no significant difference in PFS or OS was observed between BC patients and UTUC patients without RPI. CONCLUSIONS RPI was a poor prognostic factor in advanced urothelial carcinoma treated with pembrolizumab, possibly resulting in a poorer prognosis for UTUC compared with BC.
Collapse
Affiliation(s)
- Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Satoru Takahashi
- Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan
- Department of Radiology, Takatsuki General Hospital, Takatsuki, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
11
|
Ueki H, Kitagawa K, Kato M, Yanase S, Okamura Y, Bando Y, Hara T, Terakawa T, Furukawa J, Nakano Y, Fujisawa M, Shirakawa T. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model. Sci Rep 2023; 13:9994. [PMID: 37340017 DOI: 10.1038/s41598-023-37234-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 06/18/2023] [Indexed: 06/22/2023] Open
Abstract
Recently, immune checkpoint inhibitor (ICI) based combination therapies, including anti-PD-1 antibody, nivolumab with anti-CTLA-4 antibody, and ipilimumab have become the primary treatment option for metastatic or unresectable renal cell carcinoma (RCC). However, despite the combination of two ICIs, 60-70% of patients are still resistant to first-line cancer immunotherapy. In the present study, undertook combination immunotherapy for RCC using an oral cancer vaccine (Bifidobacterium longum displaying WT1 tumor associated antigen (B. longum 420)) with anti-PD-1 and anti-CTLA-4 antibodies in a mouse syngeneic model of RCC to explore possible synergistic effects. We found that B. longum 420 significantly improved the survival of mice bearing RCC tumors treated by anti-PD-1 and anti-CTLA-4 antibodies compared to the mice treated by the antibodies alone. This result suggests that B. longum 420 oral cancer vaccine as an adjunct to ICIs could provide a novel treatment option for RCC patients. Our microbiome analysis revealed that the proportion of Lactobacilli was significantly increased by B. longum 420. Although the detailed mechanism of action is unknown, it is possible that microbiome alteration by B. longum 420 enhances the efficacy of the ICIs.
Collapse
Affiliation(s)
- Hideto Ueki
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
- Laboratory of Translational Research for Biologics, Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Koichi Kitagawa
- Laboratory of Translational Research for Biologics, Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Mako Kato
- Laboratory of Translational Research for Biologics, Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Shihoko Yanase
- Laboratory of Translational Research for Biologics, Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Toshiro Shirakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
- Laboratory of Translational Research for Biologics, Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
| |
Collapse
|
12
|
Ueki H, Terakawa T, Hara T, Hirata J, Jimbo N, Okamura Y, Bando Y, Furukawa J, Harada K, Nakano Y, Fujisawa M. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer. Jpn J Clin Oncol 2023:7056727. [PMID: 36828781 DOI: 10.1093/jjco/hyad011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 02/03/2023] [Indexed: 02/26/2023] Open
Abstract
OBJECTIVE This study retrospectively reviewed the clinical characteristics and treatment outcomes of patients with histologically diagnosed treatment-related pure small-cell neuroendocrine prostate cancer. METHODS We retrospectively evaluated data for 13 patients with treatment-related neuroendocrine prostate cancer who were diagnosed between May 2015 and February 2022. Standardized systemic therapies of etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan were selected as sequential treatments. Cancer-specific survival and progression-free survival were evaluated as the primary endpoint. The Cox proportional hazards model was used to evaluate the relationships between treatment regimens, clinical variables, cancer-specific survival and progression-free survival. RESULTS The median cancer-specific survival after diagnosis for all patients was 22.4 months (range 1.3-33.4 months). The median progression-free survival was 9.3 months after first-line etoposide plus cisplatin (or carboplatin) treatment (n = 13); 4.2 months after second-line amrubicin treatment (n = 4); and >15 months after third-line nogitecan treatment (n = 2). The median progression-free survival after first-line chemotherapy of the liver metastasis (-) group was 10.2 months, and that of the (+) group was 5.3 months (P = 0.015, hazard ratio = 11.6, 95% confidence interval = 1.01 - 133.7). No clinicopathological parameters were identified as significant independent predictors of cancer-specific survival in univariate analysis. CONCLUSION Sequential chemotherapy with etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan may be helpful for patients with treatment-related pure small-cell neuroendocrine prostate cancer. Early biopsy of metastases and initiation of effective therapy is essential for patients with progressive castration-resistant prostate cancer and low prostate-specific antigen.
Collapse
Affiliation(s)
- Hideto Ueki
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junichiro Hirata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Naoe Jimbo
- Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
13
|
Wakita N, Hinata N, Bando Y, Hara T, Terakawa T, Furukawa J, Nakano Y, Fujisawa M. Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer Res 2023; 43:841-847. [PMID: 36697079 DOI: 10.21873/anticanres.16226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 12/28/2022] [Accepted: 12/30/2022] [Indexed: 01/26/2023]
Abstract
BACKGROUND/AIM Increasing availability of effective treatment options for metastatic renal cell carcinoma (mRCC) has highlighted the importance of identifying predictors of treatment response. Although PD-L1 expression in renal cancer has been reported as a predictor of treatment response and prognosis, its assessment by immunohistochemistry is invasive and difficult to perform repeatedly. Soluble PD-L1 (sPD-L1) has recently been proposed as a predictive biomarker for several tumour types. Therefore, we evaluated sPD-L1 levels in patients with mRCC treated with nivolumab and investigated its association with treatment response. PATIENTS AND METHODS We performed a prospective single-arm study in patients with mRCC treated with nivolumab as second line or later therapy. We measured serum sPD-L1 before and during treatment, classified patients based on baseline values (sPDL1 ≥0.23 ng/ml vs. <0.23 ng/ml) and compared outcomes between the two groups. RESULTS A total of 43 patients with mRCC were included in this study, with 17 (39.5%) classified as low sPD-L1 and 26 (60.5%) as high sPD-L1. The International Metastatic RCC Database Consortium risk score was significantly poorer in the high sPD-L1 group. The objective response rate was significantly higher (41.2% vs. 7.7%) and overall survival significantly longer (p=0.0323) in the low group compared to the high group. There were no significant differences in progression-free survival between the two groups. CONCLUSION Our study findings indicate that sPD-L1 might be a predictor of treatment response to nivolumab in patients with mRCC.
Collapse
Affiliation(s)
- Naoto Wakita
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan;
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.,Department of Urology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
14
|
Bando Y, Furukawa J, Hara T, Okamura Y, Terakawa T, Nakano Y, Fujisawa M. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review. Urol Int 2023; 107:321-326. [PMID: 36731453 DOI: 10.1159/000528447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 11/26/2022] [Indexed: 02/04/2023]
Abstract
Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.
Collapse
Affiliation(s)
- Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
15
|
Ueki H, Hara T, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada K, Nakano Y, Fujisawa M. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study. Investig Clin Urol 2022; 63:415-424. [PMID: 35796138 PMCID: PMC9262481 DOI: 10.4111/icu.20220028] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 04/04/2022] [Accepted: 05/18/2022] [Indexed: 12/25/2022] Open
Abstract
Purpose Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab. Materials and Methods This study evaluated 96 patients with RCC who received nivolumab. The SMI and PMI were calculated for each patient and normalized for stature by use of the following formulas: SMI (cm2/m2)=([skeletal muscle cross-sectional area at the level of L3]/[height]2) and PMI (cm2/m2) = ([left-right sum of the psoas muscle areas at the level of L3]/[height]2). The relationship of the clinical variables with progression-free survival and overall survival (OS) was examined using a Cox proportional hazards model. Results According to the SMI-based definition of sarcopenia, 74.0% of patients had sarcopenia. However, according to the PMI-based definition of sarcopenia, only 34.3% of patients were diagnosed with sarcopenia. Multivariate analysis identified sarcopenia based on PMI (hazard ratio [HR], 3.85; 95% confidence interval [CI], 2.04–7.26; p<0.001) and International Metastatic RCC Database Consortium poor risk status (HR, 1.90; 95% CI, 1.03–3.50; p=0.041) as significant and independent prognostic factors of OS. Conclusions PMI-based sarcopenia is a significant prognostic factor for OS in patients with RCC who receive nivolumab therapy.
Collapse
Affiliation(s)
- Hideto Ueki
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
16
|
Bando Y, Furukawa J, Okamura Y, Hara T, Terakawa T, Nakano Y, Fujisawa M. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma. Anticancer Res 2022; 42:973-979. [PMID: 35093897 DOI: 10.21873/anticanres.15557] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 12/16/2021] [Accepted: 12/23/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM The survival benefit of immune checkpoint inhibitors for non-clear cell renal cell carcinoma (nccRCC) is unclear. Our purpose was to evaluate the real-world survival benefit of ipilimumab plus nivolumab retrospectively. PATIENTS AND METHODS We retrospectively reviewed medical records of 33 patients with metastatic nccRCC who received combination therapy with ipilimumab plus nivolumab or monotherapy with a molecular targeted agent as initial systemic therapy. Progression-free survival (PFS), overall survival (OS) and objective response rate were compared between the two groups. RESULTS Median PFS of each therapy was 3.5 and 4.7 months (p=0.61) and median OS was 19.6 and 10.6 months (p=0.23), respectively. Three patients treated with ipilimumab and nivolumab had a complete response, resulting in an objective response rate of 30.0%, while that for molecular targeted therapy was 4.5% (p=0.04). CONCLUSION Ipilimumab plus nivolumab achieved statistically non-significant, but longer overall survival and significantly higher objective response rate.
Collapse
Affiliation(s)
- Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
17
|
Wakita N, Hinata N, Suzuki K, Bando Y, Okamura Y, Hara T, Terakawa T, Furukawa J, Harada K, Fujisawa M. Comparison of robot-assisted partial nephrectomy for complex (RENAL scores ≥10) and non-complex renal tumors: A single-center experience. Int J Urol 2021; 28:1054-1059. [PMID: 34279058 DOI: 10.1111/iju.14647] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 06/27/2021] [Indexed: 01/20/2023]
Abstract
OBJECTIVES To compare functional and surgical outcomes of robot-assisted partial nephrectomy for complex tumors with RENAL scores ≥10 and non-complex tumors at a single academic institution. METHODS We retrospectively analyzed the data of all patients who underwent robot-assisted partial nephrectomy at Kobe University Hospital (Kobe, Hyogo, Japan) from 2011 to 2020. Functional and surgical outcomes for complex tumors (RENAL score ≥10) were compared with those of patients with non-complex tumors (RENAL <10). Outcomes analyzed included blood loss, warm ischemia time, console time, perioperative complications, and preoperative and postoperative renal function. RESULTS A total of 348 patients were included in our present study, with a median follow-up time of 35.1 months. Of these, 299 patients (85.9%) had non-complex tumors and 49 patients (14.1%) had complex tumors. Warm ischemia time and console time were significantly longer in the complex tumors group. Major perioperative complications (Clavien-Dindo classification system ≥3) were significantly more frequent in the complex tumors group than the non-complex tumor group (16.3% vs 5.7%, P = 0.018). Postoperative preservation of estimated glomerular filtration rate and percentage of chronic kidney disease upstage by 1 year were significantly inferior in the complex tumors group. The positive surgical margin rate was 0% and 0.3% in the complex and non-complex tumor groups, respectively. There were no significant differences in recurrence-free survival between the two groups (P = 0.11). CONCLUSIONS Robot-assisted partial nephrectomy for complex renal tumors is safe, with no difference in oncological outcomes, although more postoperative complications and decreased renal function can be observed than non-complex tumors.
Collapse
Affiliation(s)
- Naoto Wakita
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Kotaro Suzuki
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| |
Collapse
|
18
|
Bando Y, Furukawa J, Terakawa T, Harada K, Hinata N, Nakano Y, Fujisawa M. Treatment outcomes of molecular targeted therapy following nivolumab in metastatic renal cell carcinoma. Jpn J Clin Oncol 2021; 51:1313-1318. [PMID: 33954587 DOI: 10.1093/jjco/hyab068] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 04/21/2021] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE The purpose of this study was to assess the therapeutic efficacy of molecular targeted therapies following nivolumab in metastatic renal cell carcinoma and to examine the relationship between therapeutic efficacy and the specific molecular targeted therapy used. METHODS We retrospectively reviewed the medical records of 115 metastatic renal cell carcinoma patients who were treated with nivolumab at our institution and five affiliated hospitals. Among them, 52 patients who received subsequent molecular targeted therapy following nivolumab were selected to survey treatment outcomes. Progression-free survival and overall survival were estimated with Kaplan-Meier curves, and differences were analyzed by the log-rank test. RESULTS Among the 52 eligible patients, 40 (76.9%) were treated with tyrosine kinase inhibitors and 12 (23.1%) were treated with mammalian target of rapamycin inhibitor. The median time to treatment failure and progression-free survival of subsequent molecular targeted therapy were 5.6 and 8.0 months, respectively. The median overall survival from the initiation of first-line therapy was not reached. The disease control rate of subsequent molecular targeted therapy was 69.2% (partial response: 25.0%, stable disease: 44.2%). The median progression-free survival of subsequent tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor were 9.2 and 8.0 months, respectively (P = 0.37). The progression-free survival of patients whose best response to prior nivolumab was either progressive disease or stable disease/partial response were 6.3 and 11.3 months, respectively (P = 0.36). CONCLUSIONS Molecular targeted therapies following nivolumab had comparatively better therapeutic efficacy, which was confirmed regardless of the type of molecular targeted agent used.
Collapse
Affiliation(s)
- Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
19
|
Okamura Y, Terakawa T, Sakamoto M, Bando Y, Suzuki K, Hara T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis. In Vivo 2020; 33:2013-2019. [PMID: 31662532 DOI: 10.21873/invivo.11698] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 07/23/2019] [Accepted: 07/24/2019] [Indexed: 01/05/2023]
Abstract
Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. MATERIALS AND METHODS We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. RESULTS Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). CONCLUSION Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.
Collapse
Affiliation(s)
- Yasuyoshi Okamura
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Mariko Sakamoto
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kotaro Suzuki
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuto Hara
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
20
|
Bando Y, Hinata N, Terakawa T, Furukawa J, Harada K, Nakano Y, Fujisawa M. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histopathological and molecular analyses. Prostate 2020; 80:345-351. [PMID: 31899555 DOI: 10.1002/pros.23949] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 12/23/2019] [Indexed: 02/02/2023]
Abstract
BACKGROUND The optimal extent of lymph node dissection in radical prostatectomy has not been determined. Lymph nodes in the fossa of Marcille, which is an important pelvic lymphatic pathway and candidate for additional dissection, have not been evaluated at the molecular level. Here, we assessed by molecular analysis the presence of occult positive lymph nodes in the fossa of Marcille in patients with clinically localized high-risk prostate cancer. METHODS Fifty-two patients with clinically localized high-risk prostate cancer underwent pelvic lymph node dissection accompanied by robot-assisted radical prostatectomy. All nodal packets were dissected separately and grouped into right and left obturator, external and internal iliac regions (including common iliac region to ureter crossing), and fossa of Marcille. All lymph nodes were bisected and evaluated by histopathological or molecular analysis using a quantitative reverse transcription-polymerase chain reaction. The number of positive lymph nodes in the fossa of Marcille and the difference in detection rate were investigated using histopathological and molecular analyses. Perioperative complication rate and predictive factors for biochemical recurrence were evaluated. RESULTS In the molecular analysis, there were seven positive lymph nodes in the fossa of Marcille in three patients, which were coexistent with positive nodes in other regions. The detection rate of positive lymph nodes was significantly higher using molecular than histopathological analysis (P < .01). Perioperative complication rate within 90 days after the operation was 25.0% and no Clavien-Dindo grade ≥3 complication was confirmed. Detection of metastasis by histopathological and molecular analysis was a significant factor related to biochemical recurrence in the Cox proportional hazards regression model. CONCLUSIONS No case of positive lymph nodes in the fossa of Marcille that had skipped over other regions was confirmed. Additional lymph node dissection of fossa of Marcille did not lead to complete resection of molecularly positive lymph nodes.
Collapse
Affiliation(s)
- Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tomoaki Terakawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
21
|
Bando Y, Hinata N, Omori T, Fujisawa M. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma. BMJ Open 2019; 9:e030522. [PMID: 31826889 PMCID: PMC6924736 DOI: 10.1136/bmjopen-2019-030522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2019] [Revised: 11/01/2019] [Accepted: 11/07/2019] [Indexed: 01/05/2023] Open
Abstract
INTRODUCTION Nivolumab has been proven to prolong overall survival as a second-line therapy for patients with advanced renal cell carcinoma (RCC) in a phase III clinical trial. However, versatile biomarkers have not been established to predict the efficacy of nivolumab against target disease. METHODS AND ANALYSIS After registration, screening test and serum-soluble programmed cell death 1-ligand 1 (sPD-L1) measurement will be performed by using the ELISA; patients will be grouped into high sPD-L1 or low sPD-L1 groups. Nivolumab (240 mg every 2 weeks by intravenous drip infusion) will be administered to each participant. For this prospective study, statistical power calculation indicated that 48 participants with metastatic or unresectable RCC are needed to assess the efficacy of this method. The participants must be at the age of at least 20 years at the time of informed consent and require second-line therapy after failure of first-line therapy or discontinuation due to adverse effects. All data will be collected in our institution. The primary endpoint is progression-free survival, and secondary endpoints are overall survival and objective response rate. In this protocol, we will examine sPD-L1 as a promising predictive marker. ETHICS AND DISSEMINATION This protocol was approved by the Kobe University Clinical Research Ethical Committee (C180067). Findings of this study will be widely disseminated through conference presentations, reports, factsheets and academic publications; further generalisation will also be discussed. TRIAL REGISTRATION NUMBER UMIN000027873.
Collapse
Affiliation(s)
- Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine School of Medicine, Kobe, Hyogo, Japan
| | - Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine School of Medicine, Kobe, Hyogo, Japan
| | - Takashi Omori
- Center Administration Division, Center for Clinical Research, Kobe University Hospital, Kobe, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine School of Medicine, Kobe, Hyogo, Japan
| |
Collapse
|
22
|
Hinata N, Bando Y, Chiba K, Furukawa J, Harada K, Ishimura T, Nakano Y, Fujisawa M. Application of hyaluronic acid/carboxymethyl cellulose membrane for early continence after nerve-sparing robot-assisted radical prostatectomy. BMC Urol 2019; 19:25. [PMID: 31014320 PMCID: PMC6480847 DOI: 10.1186/s12894-019-0458-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 04/10/2019] [Indexed: 12/28/2022] Open
Abstract
Background To assess whether application of a hyaluronic acid-carboxymethyl cellulose membrane (HA/CMC) to the prostate bed and neurovascular plate facilitated early return of continence after nerve-sparing robot-assisted radical prostatectomy (RARP). Methods The subjects were 183 consecutive patients with organ-confined prostate cancer who underwent unilateral or bilateral nerve-sparing RARP. After vesicourethral anastomosis, HA/CMC was placed to cover Denonvilliers’ fascia (behind the anastomotic suture) and the preserved neurovascular plate. The time until complete continence after RARP and perioperative complications were compared between patients with or without HA/CMC. Results HA/CMC was applied in 13/46 patients (28.3%) receiving bilateral nerve-sparing surgery and 40/137 patients (29.2%) receiving unilateral nerve-sparing surgery. After bilateral nerve-sparing RARP, the median time until continence was significantly shorter in patients with HA/CMC than in those without HA/CMC (3.2 vs. 9.3 months, respectively, p < 0.01). After unilateral nerve-sparing RARP, the median time until continence was also significantly shorter in patients with HA/CMC than in those without HA/CMC (3.2 vs. 12.0 months, respectively, p < 0.01). Multivariate Cox proportional hazards regression analysis showed that an age < 70 years (hazard ratio [HR]: 1.74, 95% confidence interval [CI]: 1.12–2.80), institutional caseload > 200, (HR: 1.64, 95%CI: 1.10–2.47), and use of HA/CMC (HR: 1.84, 95%CI: 1.22–2.76) were independent predictors of early postoperative continence. Complication rates, including urinary leakage, did not differ significantly between patients with or without HA/CMC. Conclusion Application of HA/CMC to the prostate bed and neurovascular plate resulted in significantly faster postoperative return of continence after both unilateral and bilateral nerve-sparing RARP.
Collapse
Affiliation(s)
- Nobuyuki Hinata
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan. .,Training Center for Advanced Surgery and Endoscopy, Kobe University School of Medicine, Kobe, Japan.
| | - Yukari Bando
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Koji Chiba
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Junya Furukawa
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Kenichi Harada
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Takeshi Ishimura
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Yuzo Nakano
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| | - Masato Fujisawa
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan
| |
Collapse
|
23
|
Harada K, Shiraishi Y, Suzuki K, Okamura Y, Bando Y, Hara T, Terakawa T, Furukawa J, Ishimura T, Shigemura K, Hinata N, Nakano Y, Fujisawa M. [EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA: A SINGLE-INSTITUTION STUDY]. Nihon Hinyokika Gakkai Zasshi 2018; 109:216-219. [PMID: 31631085 DOI: 10.5980/jpnjurol.109.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
To investigate the efficacy and safety of first-line Pazopanib advanced or metastatic renal cell carcinoma (RCC): a single-institution study. (Patients and methods) We gathered 23 RCC patients treated between April 2014 and February 2018 in our institution and examined the treatments outcome and adverse events (AEs). (Results) Their risk criteria were categorized as follows: Favorable (n=2), Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion (IMDC). Median progression free survival (PFS) was 8.6 months and median overall survival (OS) was unreached. Best response (BR) of Pazopanib was partial response (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting (n=1) and bowel bleeding (n=1). (Conclusion) The fist-line pazopanib demonstrated good clinical benefit with well-tolerance.
Collapse
Affiliation(s)
- Kenichi Harada
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Yusuke Shiraishi
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Kohtaro Suzuki
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | | | - Yukari Bando
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Takuto Hara
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Tomoaki Terakawa
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Junya Furukawa
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Takeshi Ishimura
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | | | - Nobuyuki Hinata
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Yuzo Nakano
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| | - Masato Fujisawa
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
| |
Collapse
|
24
|
Jang HS, Hinata N, Cho KH, Bando Y, Murakami G, Abe SI. Nerves in the cavernous tissue of the glans penis: An immunohistochemical study using elderly donated cadavers. J ANAT SOC INDIA 2017. [DOI: 10.1016/j.jasi.2017.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Hiraiwa H, Okumura T, Sawamura A, Sugiura Y, Kondo T, Watanabe N, Aoki S, Ichii T, Kano N, Fukaya K, Furusawa K, Morimoto R, Takeshita K, Bando Y, Murohara T. P712The Selvester QRS score as a predictor of cardiac events in nonischemic dilated cardiomyopathy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H. Hiraiwa
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - T. Okumura
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - A. Sawamura
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - Y. Sugiura
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - T. Kondo
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - N. Watanabe
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - S. Aoki
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - T. Ichii
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - N. Kano
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - K. Fukaya
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - K. Furusawa
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - R. Morimoto
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - K. Takeshita
- Nagoya University Hospital, Department of Clinical Laboratory, Nagoya, Japan
| | - Y. Bando
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | - T. Murohara
- Nagoya University, Department of Cardiology, Nagoya, Japan
| | | |
Collapse
|
26
|
Hinata N, Hussein AA, Terakawa T, Bando Y, Murakami G, Guru K, Fujisawa M. MP81-09 THE NERVES IN THE GLANS PENIS: ANATOMICAL AND HISTOLOGICAL STUDY. J Urol 2017. [DOI: 10.1016/j.juro.2017.02.2535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Iihara N, Bando Y, Ohara M, Yoshida T, Nishio T, Okada T, Kirino Y. Polypharmacy of medications and fall-related fractures in older people in Japan: a comparison between driving-prohibited and driving-cautioned medications. J Clin Pharm Ther 2016; 41:273-8. [DOI: 10.1111/jcpt.12381] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 02/22/2016] [Indexed: 12/12/2022]
Affiliation(s)
- N. Iihara
- Kagawa School of Pharmaceutical Sciences; Tokushima Bunri University; Sanuki-City Kagawa Japan
| | - Y. Bando
- Faculty of Health and Welfare; Tokushima Bunri University; Sanuki-City Kagawa Japan
| | - M. Ohara
- Ayagawa National Health Insurance Sue Hospital; Ayauta-gun Kagawa Japan
| | - T. Yoshida
- Faculty of Health and Welfare; Tokushima Bunri University; Sanuki-City Kagawa Japan
| | - T. Nishio
- Graduate School of Pharmaceutical Sciences; Tokushima Bunri University; Sanuki-City Kagawa Japan
- Department of Pharmacy; Sanuki City Hospital; Sanuki-City Kagawa Japan
| | - T. Okada
- Kagawa School of Pharmaceutical Sciences; Tokushima Bunri University; Sanuki-City Kagawa Japan
| | - Y. Kirino
- Kagawa School of Pharmaceutical Sciences; Tokushima Bunri University; Sanuki-City Kagawa Japan
| |
Collapse
|
28
|
Ide Y, Nagao K, Saito K, Komaguchi K, Fuji R, Kogure A, Sugahara Y, Bando Y, Golberg D. h-BN nanosheets as simple and effective additives to largely enhance the activity of Au/TiO2 plasmonic photocatalysts. Phys Chem Chem Phys 2016; 18:79-83. [DOI: 10.1039/c5cp05958e] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Au/TiO2 plasmonic photocatalysts showed largely enhanced activity for the oxidation of formic acid in water into CO2 when simply mixed with h-BN nanosheets, as a result of electron transfer from photoexcited Au/TiO2 to the additive to retard charge recombination.
Collapse
Affiliation(s)
- Y. Ide
- International Center for Materials Nanoarchitectonics (WPI-MANA)
- National Institute for Materials Science (NIMS)
- Tsukuba
- Japan
- Graduate School of Creative Science and Engineering
| | - K. Nagao
- Graduate School of Creative Science and Engineering
- Waseda University
- Tokyo 169-8050
- Japan
| | - K. Saito
- Graduate School of Creative Science and Engineering
- Waseda University
- Tokyo 169-8050
- Japan
| | - K. Komaguchi
- Graduate School of Engineering
- Department of Applied Chemistry
- Hiroshima University
- Higashi-Hiroshima 739-8527
- Japan
| | - R. Fuji
- Shimadzu Cooperation
- Hadano-shi
- Japan
| | - A. Kogure
- Shimadzu Techno-Research
- INC
- Hadano-shi
- Japan
| | - Y. Sugahara
- Graduate School of Creative Science and Engineering
- Waseda University
- Tokyo 169-8050
- Japan
- Department of Applied Chemistry
| | - Y. Bando
- International Center for Materials Nanoarchitectonics (WPI-MANA)
- National Institute for Materials Science (NIMS)
- Tsukuba
- Japan
| | - D. Golberg
- International Center for Materials Nanoarchitectonics (WPI-MANA)
- National Institute for Materials Science (NIMS)
- Tsukuba
- Japan
| |
Collapse
|
29
|
Miyamoto T, Bando Y, Koh E, Tsujimura A, Miyagawa Y, Iijima M, Namiki M, Shiina M, Ogata K, Matsumoto N, Sengoku K. A PLK4 mutation causing azoospermia in a man with Sertoli cell-only syndrome. Andrology 2015; 4:75-81. [PMID: 26452337 DOI: 10.1111/andr.12113] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 08/27/2015] [Accepted: 08/27/2015] [Indexed: 01/31/2023]
Abstract
About 15% of couples wishing to have children are infertile; approximately half these cases involve a male factor. Polo-like kinase 4 (PLK-4) is a member of the polo protein family and a key regulator of centriole duplication. Male mice with a point mutation in the Plk4 gene show azoospermia associated with germ cell loss. Mutational analysis of 81 patients with azoospermia and Sertoli cell-only syndrome (SCOS) identified one man with a heterozygous 13-bp deletion in the Ser/Thr kinase domain of PLK4. Division of centrioles occurred in wild-type PLK4-transfected cells, but was hampered in PLK-4-mutant transfectants, which also showed abnormal nuclei. Thus, this PLK4 mutation might be a cause of human SCOS and nonobstructive azoospermia.
Collapse
Affiliation(s)
- T Miyamoto
- Departments of Obstetrics and Gynecology, Asahikawa Medical University, Asahikawa, Japan
| | - Y Bando
- Functional Anatomy and Neuroscience, Asahikawa Medical University, Asahikawa, Japan
| | - E Koh
- Department of Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - A Tsujimura
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Miyagawa
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
| | - M Iijima
- Department of Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - M Namiki
- Department of Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
| | - M Shiina
- Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - K Ogata
- Department of Biochemistry, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - N Matsumoto
- Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - K Sengoku
- Departments of Obstetrics and Gynecology, Asahikawa Medical University, Asahikawa, Japan
| |
Collapse
|
30
|
Murakami K, Tanaka T, Bando Y, Yoshida S. Nerve injury induces the expression of syndecan-1 heparan sulfate proteoglycan in primary sensory neurons. Neuroscience 2015; 300:338-50. [PMID: 26002314 DOI: 10.1016/j.neuroscience.2015.05.033] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Revised: 04/26/2015] [Accepted: 05/13/2015] [Indexed: 12/18/2022]
Abstract
Heparan sulfate proteoglycans (HSPGs) have important functions in development of the central nervous system; however, their functions in nerve injury are not yet fully understood. We previously reported the expression of syndecan-1, a type of HSPG, in cranial motor neurons after nerve injury, suggesting the importance of syndecan-1 in the pathology of motor nerve injury. In this study, we examined the expression of syndecan-1, a type of HSPG, in primary sensory neurons after nerve injury in mice. Sciatic nerve axotomy strongly induced the expression of syndecan-1 in a subpopulation of injured dorsal root ganglion (DRG) neurons, which were small in size and had CGRP- or isolectin B4-positive fibers. Syndecan-1 was also distributed in the dorsal horn of the spinal cord ipsilateral to the axotomy, and located on the membrane of axons in lamina II of the dorsal horn. Not only sciatic nerve axotomy, infraorbital nerve axotomy also induced the expression of syndecan-1 in trigeminal ganglion neurons. Moreover, syndecan-1 knockdown in cultured DRG neurons induced a shorter neurite extension. These results suggest that syndecan-1 expression in injured primary sensory neurons may have functional roles in nerve regeneration and synaptic plasticity, resulting in the development of neuropathic pain.
Collapse
Affiliation(s)
- K Murakami
- Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Japan.
| | - T Tanaka
- Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Japan
| | - Y Bando
- Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Japan
| | - S Yoshida
- Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Japan
| |
Collapse
|
31
|
Kido J, Bando Y, Bando M, Kajiura Y, Hiroshima Y, Inagaki Y, Murata H, Ikuta T, Kido R, Naruishi K, Funaki M, Nagata T. YKL-40 level in gingival crevicular fluid from patients with periodontitis and type 2 diabetes. Oral Dis 2015; 21:667-73. [PMID: 25740558 DOI: 10.1111/odi.12334] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Revised: 02/16/2015] [Accepted: 02/25/2015] [Indexed: 01/15/2023]
Abstract
OBJECTIVE YKL-40 is a chitin-binding glycoprotein, the level of which increases in inflammatory diseases, diabetes mellitus (DM), cardiovascular diseases, and tumors. Gingival crevicular fluid (GCF) contains many proteins and markers of periodontitis. The purpose of this study was to investigate YKL-40 level in GCF from patients with periodontitis and DM and the association between YKL-40 level and chronic periodontitis (CP) or DM. SUBJECTS AND METHODS The subjects were 121 patients with DM, CP, DM and periodontitis (DM-P), and healthy subjects (H). GCF was collected using paper strips after the sites for GCF collection were clinically evaluated for probing depth (PD), gingival index (GI), and bleeding on probing (BOP). YKL-40 in GCF was identified by Western blotting, and its level was determined by ELISA. RESULTS YKL-40 was contained in GCF samples from H, DM, CP, and DM-P sites, and its levels (amount and concentration) in CP and DM-P were significantly higher than those in H and DM. GCF YKL-40 level significantly correlated with PD and GI, and its level in BOP-positive sites was significantly higher than that in BOP-negative ones. CONCLUSIONS GCF YKL-40 level was elevated in periodontitis, but not DM. YKL-40 in GCF may be an inflammatory marker for periodontitis.
Collapse
Affiliation(s)
- J Kido
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - Y Bando
- Clinical Research Center for Diabetes, Tokushima University Hospital, Tokushima, Japan
| | - M Bando
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - Y Kajiura
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - Y Hiroshima
- Clinical Research Center for Diabetes, Tokushima University Hospital, Tokushima, Japan
| | - Y Inagaki
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - H Murata
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - T Ikuta
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - R Kido
- Department of Anatomy and Cell Biology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - K Naruishi
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| | - M Funaki
- Clinical Research Center for Diabetes, Tokushima University Hospital, Tokushima, Japan
| | - T Nagata
- Department of Periodontology and Endodontology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan
| |
Collapse
|
32
|
Morimoto R, Okumura T, Shimizu S, Shimazu S, Yamada T, Hirashiki A, Takeshita K, Bando Y, Kondo T, Murohara T. Impaired force-frequency relation pattern as a novel prognostic predictor in patients with hypertrophic cardiomyopathy. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Toba H, Kondo K, Sadohara Y, Otsuka H, Morimoto M, Kajiura K, Nakagawa Y, Yoshida M, Kawakami Y, Takizawa H, Kenzaki K, Sakiyama S, Bando Y, Tangoku A. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1 , glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg 2013; 44:e105-12. [DOI: 10.1093/ejcts/ezt263] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
34
|
Wu XC, Tao YR, Li L, Bando Y, Golberg D. Centimeter-long Ta3N5 nanobelts: synthesis, electrical transport, and photoconductive properties. Nanotechnology 2013; 24:175701. [PMID: 23548821 DOI: 10.1088/0957-4484/24/17/175701] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Centimeter-long Ta3N5 nanobelts were synthesized by a reaction of centimeter-long TaS3 nanobelt templates with flowing NH3 at 800 °C for 2 h. The nanobelts have cross-sections of about 50 × 100 nm(2), and lengths up to 0.5 cm. A field effect transistor (FET) made of a single Ta3N5 nanobelt was fabricated on silica/silicon substrate. The electric transport of the individual nanobelt revealed that the nanobelt is a semiconductor with a room-temperature resistivity of 11.88 Ω m, and can be fitted well with an empirical formula ρ = 10831 exp(-T/43.8) - 22.6, where ρ is resistivity (Ω m) and T is absolute temperature (K). The FET showed decent photoconductive performance under light irradiation in the range 250-630 nm. The photocurrent increased by nearly 10 times the dark current under 450 nm light irradiation at an applied voltage of 5.0 V.
Collapse
Affiliation(s)
- X C Wu
- Key Laboratory of Mesoscopic Chemistry of MOE, and School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, People's Republic of China.
| | | | | | | | | |
Collapse
|
35
|
Abstract
Obesity and type 2 diabetes (T2D) are characterized by decreased insulin sensitivity and higher concentrations of free fatty acids (FFAs) in plasma. Among FFAs, saturated fatty acids (SFAs), such as palmitate, have been proposed to promote inflammatory responses. Primary Sjögren's syndrome (SS) is an autoimmune disease characterized by inflammatory mononuclear cell infiltration and destruction of epithelial cells in the salivary and lacrimal glands. IL-6 production and α-fodrin degradation are increased in salivary gland epithelial cells of patients with primary SS. Although previous studies have shown a link between SS and either dyslipidemia or T2D, little is known about the clinical significance of FFAs in primary SS. Here we report that SFAs, but not unsaturated fatty acids, induced IL-6 production via NF-κB and p38 MAPK activation in human salivary gland epithelial cells. Moreover, palmitate induced apoptosis and α-fodrin degradation by caspase-3 activation. Unlike salivary gland epithelial cells, induction of IL-6 production and the degradation of α-fodrin in response to palmitate were undetectable in squamous carcinoma cells and keratinocytes. Taken together, SFAs induced IL-6 production and α-fodrin degradation in salivary gland epithelial cells, implicating a potential link between the pathogenesis of primary SS and SFAs level in plasma.
Collapse
Affiliation(s)
- Y Shikama
- Clinical Research Center for Diabetes, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima 770-8503, Japan.
| | | | | | | | | | | | | |
Collapse
|
36
|
Murakami K, Jiang YP, Tanaka T, Bando Y, Mitrovic B, Yoshida S. In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins. Neuroscience 2013; 236:1-11. [PMID: 23376368 DOI: 10.1016/j.neuroscience.2012.12.073] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Revised: 11/30/2012] [Accepted: 12/22/2012] [Indexed: 01/19/2023]
Abstract
Oligodendrocytes are important for not only nerve conduction but also central nervous system (CNS) development and neuronal survival in a variety of conditions. Kallikrein-related peptidase 6 (KLK6) is expressed in oligodendrocytes in the CNS and its expression is changed in several physiological and pathological conditions, especially following spinal cord injury (SCI) and experimental autoimmune encephalomyelitis. In this study, we investigated the functions of KLK6 in oligodendrocyte lineage cell development and the production of myelin proteins using KLK6-deficient (KLK6(-/-)) mice. KLK6(-/-) mice were born without apparent defects and lived as long as wild-type (WT) mice. There was no significant difference in the numbers of oligodendrocyte precursor cells and mature oligodendrocytes in the adult naive spinal cord between WT and KLK6(-/-) mice. However, there were fewer mature oligodendrocytes in the KLK6(-/-) spinal cord than in the WT spinal cord at postnatal day 7 (P7). Expression of myelin basic protein (MBP) and oligodendrocyte-specific protein/claudin-11, major myelin proteins, was also decreased in the KLK6(-/-) spinal cord compared with the WT spinal cord at P7-21. Moreover, after SCI, the amount of MBP in the damaged spinal cords of KLK6(-/-) mice was significantly less than that in the damaged spinal cords of WT mice. These results indicate that KLK6 plays a functional role in oligodendrocyte development and the expression of myelin proteins.
Collapse
Affiliation(s)
- K Murakami
- Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Asahikawa, Japan.
| | | | | | | | | | | |
Collapse
|
37
|
Tatemoto Y, Michikoshi T, Higashino T, Maeda S, Maeda S, Bando Y. Behavior of Pieces of Plastic Sheet in Solid-Liquid Fluidized Bed with Stirring. Chem Eng Technol 2012. [DOI: 10.1002/ceat.201200201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
38
|
Bando Y. [The functional role of stress proteins in ER-stress mediated cell death]. Kaibogaku Zasshi 2011; 86:75-76. [PMID: 21950014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
39
|
Bando Y, Mitomo M, Kitami Y, Izumi F. Structure and composition analysis of silicon aluminium oxynitride polytypes by combined use of structure imaging and microanalysis. J Microsc 2011. [DOI: 10.1111/j.1365-2818.1986.tb02760.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
40
|
Han G, Weber D, Neubrech F, Yamada I, Mitome M, Bando Y, Pucci A, Nagao T. Infrared spectroscopic and electron microscopic characterization of gold nanogap structure fabricated by focused ion beam. Nanotechnology 2011; 22:275202. [PMID: 21597137 DOI: 10.1088/0957-4484/22/27/275202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Using infrared spectroscopy of plasmonic resonances and mapping of elemental composition and structure, we investigated the correlation between optical and structural properties of nanometre-scale gaps in gold nanorod dimers fabricated by electron beam lithography (EBL) and focused ion beam (FIB) milling. In spite of their very similar scanning electron microscopy (SEM) images, a fully cut nanogap and a shallower cut with slight imperfection near the gap region were clearly distinguished by their strongly different infrared plasmonic resonance behaviour. The differences in the infrared spectra are related to different structural and chemical results from elaborated cross-sectional transmission electron micrographs and energy dispersive x-ray spectrometry (EDX) mapping of the gap region.
Collapse
Affiliation(s)
- G Han
- International Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), 1-1 Namiki, Tsukuba, Ibaraki, 305-0044, Japan
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Tatemoto Y, Higashino T, Suzuki Y, Michikoshi T, Maeda S, Bando Y. Prediction of the Behavior of a Liquid-Fluidized Bed of Inert Particles Used for Separation by Density. Chem Eng Technol 2011. [DOI: 10.1002/ceat.201100012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
42
|
Li L, Zhang YX, Fang XS, Zhai TY, Liao MY, Wang HQ, Li GH, Koide Y, Bando Y, Golberg D. Sb(2)O(3) nanobelt networks for excellent visible-light-range photodetectors. Nanotechnology 2011; 22:165704. [PMID: 21393818 DOI: 10.1088/0957-4484/22/16/165704] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Excellent photoconductive properties have been found in Sb(2)O(3) nanobelts synthesized by a surfactant-assisted solvothermal method. Visible-light photodetectors have been designed from Sb(2)O(3) nanobelt networks using micrometer-wide gold wires as masks. Photodetectors show high sensitivity to visible light, high stability, and reproducibility. Fast response and decay times (<0.3 s) are comparable or even better than these parameters in many other metal oxide nanoscale photodetectors. The dominant mechanism of excellent photoconductivity is attributed to the barrier height modulations in the nanobelt-to-nanobelt contact regions. These results demonstrate that Sb(2)O(3) nanobelt networks can indeed serve as high-performance photodetectors in the visible light range.
Collapse
Affiliation(s)
- L Li
- International Center for Materials Nanoarchitectonics (MANA), National Institute for Materials Science (NIMS), Namiki 1-1, Tsukuba, Ibaraki 305-0044, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Golberg D, Bando Y, Han W, Bourgeois L, Kurashima K, Sato T. Multi-and Single-Walled Boron Nitride Nanotubes Produced From Carbon Nanotubes by a Substitution Reaction. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-593-27] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTBoron nitride (BN) multi-walled (MWNT) or single-walled (SWNT) nanotubes were synthesized from carbon MWNT and SWNT templates, respectively, under heating of C nanotubes together with boron trioxide in a flowing nitrogen atmosphere. B and N atom substitution for C atoms in the nanotubular shells during C oxidation by the B2O3 vapor in the N2 flow is thought to underlie the formation mechanism. Structural and chemical BN MWNT/SWNT analyses were performed by means of high-resolution electron microscopy (HRTEM) and electron energy loss spectroscopy (EELS), respectively. In particular, BN MWNT shell structure and defects, and electron irradiation stability were studied. Finally, the prospects of using the substitution technique for the synthesis of other advanced nanostructures made of BN (nanorods, nanoplates and nanocones) are discussed.
Collapse
|
44
|
Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010; 102:908-15. [PMID: 20145615 PMCID: PMC2833250 DOI: 10.1038/sj.bjc.6605558] [Citation(s) in RCA: 179] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Background: The Toll-like receptor (TLR) 4 signalling pathway has been shown to have oncogenic effects in vitro and in vivo. To demonstrate the role of TLR4 signalling in colon tumourigenesis, we examined the expression of TLR4 and myeloid differentiation factor 88 (MyD88) in colorectal cancer (CRC). Methods: The expression of TLR4 and MyD88 in 108 CRC samples, 15 adenomas, and 15 normal mucosae was evaluated by immunohistochemistry, and the correlations between their immunoscores and clinicopathological variables, including disease-free survival (DFS) and overall survival (OS), were analysed. Results: Compared with normal mucosae and adenomas, 20% cancers displayed high expression of TLR4, and 23% cancers showed high expression of MyD88. The high expression of TLR4 and MyD88 was significantly correlated with liver metastasis (P=0.0001, P=0.0054). In univariate analysis, the high expression of TLR4 was significantly associated with shorter OS (hazard ratio (HR): 2.17; 95% confidence interval (95% CI): 1.15–4.07; P=0.015). The high expression of MyD88 expression was significantly associated with poor DFS and OS (HR: 2.33; 95% CI: 1.31–4.13; P=0.0038 and HR: 3.03; 95% CI: 1.67–5.48; P=0.0002). The high combined expression of TLR4 and MyD88 was also significantly associated with poor DFS and OS (HR: 2.25; 95% CI: 1.27–3.99; P=0.0053 and HR: 2.97; 95% CI: 1.64–5.38; P=0.0003). Multivariate analysis showed that high expressions of TLR4 (OS: adjusted HR: 1.88; 95% CI: 0.99–3.55; P=0.0298) and MyD88 (DFS: adjusted HR: 1.93; 95% CI: 1.01–3.67; P=0.0441; OS: adjusted HR: 2.25; 95% CI: 1.17–4.33; P=0.0112) were independent prognostic factors of OS. Furthermore, high co-expression of TLR4/MyD88 was strongly associated with both poor DFS and OS. Conclusion: Our findings suggest that high expression of TLR4 and MyD88 is associated with liver metastasis and is an independent predictor of poor prognosis in patients with CRC.
Collapse
Affiliation(s)
- E L Wang
- Department of Human Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
A submicrometer-sized pH sensor based on biotin-fluorescein-functionalized multiwalled BN nanotubes with anchored Ag nanoparticles is designed. Intrinsic pH-dependent photoluminescence and Raman signals in attached fluorescein molecules enhanced by Ag nanoparticles allow this novel nanohybrid to perform as a practical pH sensor. It is able to work in a submicrometer-sized space. For example, the sensor may determine the environmental pH of sub-units in living cells where a traditional optical fiber sensor fails because of spatial limitations.
Collapse
Affiliation(s)
- Q Huang
- World Premier International Center for Materials Nanoarchitectonics, National Institute for Materials Science, Namiki 1-1, Tsukuba, Ibaraki 305-0044, Japan.
| | | | | | | | | |
Collapse
|
46
|
|
47
|
Wang JB, Li K, Zhong XL, Zhou YC, Fang XS, Tang CC, Bando Y. Considerable Enhancement of Field Emission of SnO(2) Nanowires by Post-Annealing Process in Oxygen at High Temperature. Nanoscale Res Lett 2009; 4:1135-1140. [PMID: 20596286 PMCID: PMC2894354 DOI: 10.1007/s11671-009-9367-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Accepted: 05/28/2009] [Indexed: 05/27/2023]
Abstract
The field emission properties of SnO(2) nanowires fabricated by chemical vapor deposition with metallic catalyst-assistance were investigated. For the as-fabricated SnO(2) nanowires, the turn-on and threshold field were 4.03 and 5.4 V/mum, respectively. Considerable enhancement of field emission of SnO(2) nanowires was obtained by a post-annealing process in oxygen at high temperature. When the SnO(2) nanowires were post-annealed at 1,000 degrees C in oxygen, the turn-on and threshold field were decreased to 3.77 and 4.4 V/mum, respectively, and the current density was increased to 6.58 from 0.3 mA/cm(2) at the same applied electric field of 5.0 V/mum.
Collapse
Affiliation(s)
- JB Wang
- Institute of Modern Physics, Xiangtan University, 411105, Xiangtan, Hunan, China
- Key Laboratory of Low Dimensional Materials and Application Technology of Ministry of Education, Xiangtan University, 411105, Xiangtan, Hunan, China
| | - K Li
- Institute of Modern Physics, Xiangtan University, 411105, Xiangtan, Hunan, China
- Key Laboratory of Low Dimensional Materials and Application Technology of Ministry of Education, Xiangtan University, 411105, Xiangtan, Hunan, China
| | - XL Zhong
- Institute of Modern Physics, Xiangtan University, 411105, Xiangtan, Hunan, China
- Key Laboratory of Low Dimensional Materials and Application Technology of Ministry of Education, Xiangtan University, 411105, Xiangtan, Hunan, China
| | - YC Zhou
- Institute of Modern Physics, Xiangtan University, 411105, Xiangtan, Hunan, China
- Key Laboratory of Low Dimensional Materials and Application Technology of Ministry of Education, Xiangtan University, 411105, Xiangtan, Hunan, China
| | - XS Fang
- Nanoscale Materials Center, National Institute for Materials Science, Tsukuba, 3050047, Japan
| | - CC Tang
- Nanoscale Materials Center, National Institute for Materials Science, Tsukuba, 3050047, Japan
| | - Y Bando
- Nanoscale Materials Center, National Institute for Materials Science, Tsukuba, 3050047, Japan
| |
Collapse
|
48
|
Okazaki K, Kira M, Yamai H, Nakagawa Y, Nagao T, Kenzaki K, Bando Y, Morimoto T, Kondo K, Tangoku A. Phase II trial report of the new neoadjuvant chemotherapy with S-1 and docetaxel for advanced breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1121 Background: Primary chemotherapy with anthracycline and taxanes is a gold standard regimen which realize pathologically complete response in 20% of patients with advanced breast cancer. However, sequential administration of anthracycline and taxanes induces serious side effects. This regimen is therefore difficult to use for higj-risk patients. S-1 is a new oral anti-tumor drug, which is composed of 5-fluoro-1-(tetrahydro -2- furanyl)-2, 4(1H, 3H)-pyrimidinedione (Tegafur, FT), 5-chloro-2, 4- dihydroxypyridine (Gimeracil, CDHP) and potassium 1, 2, 3, 4-tetrahydro-2, 4-dioxo-1, 3, 5-triazine-6-carboxylate (potassium Oteracil, Oxo). Combined treatment with docetaxel and S-1 yielded significant response in patients with gastric cancer with minimal side effects due to biochemical modulation of both CDHP and Oxo. The purpose of this study was to evaluate the efficacy and toxicity of docetaxel in combination with S-1 for advanced breast cancer. Methods: Patients with advanced breast cancer (Stage IIA to IV) were treated with i.v. docetaxel (40mg/m2) on day 1 and oral S-1(80mg as FT/m2/day) on days 1 to 14 every 3 weeks for 8 courses. The clinical response was evaluated every 3 months with MMG, MRI, ultrasonography and CT scan based on RECIST criteria. The patients underwent surgery after completion of chemotherapy. Pathologic examination was performed with thin-sliced specimens. The specimens were also reserved for genetic analysis. Written informed consent was obtained from all patients or family members after the Ethics Committee of Tokushima University Hospital approved the study protocol. Results: Twenty-two patients completed the therapy and underwent surgery. Four cases (18.2%) of pathologic complete response (pCR) were recognized on pathologic examination. The response rate was 90.9% and 95.5% of the patients could preserved their breast. Bone marrow suppression was substantial, and low-grade anorexia, nausea, and peripheral neuropathy were observed. Conclusions: The new regimen of S-1 combined with docetaxel is expected to exhibit satisfactory efficacy in treating advanced breast cancer as primary chemotherapy. Genetic analysis will be performed to examine and to find biomarkers for measurement of the efficacy of this therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Okazaki
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - M. Kira
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - H. Yamai
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - Y. Nakagawa
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - T. Nagao
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - K. Kenzaki
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - Y. Bando
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - T. Morimoto
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - K. Kondo
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| | - A. Tangoku
- The University of Tokushima Graduate School, Tokushima, Japan; Department of Pathology, Tokushima University Hospital, Tokushima, Japan
| |
Collapse
|
49
|
Toba H, Sakiyama S, Morimoto M, Takizawa H, Kenzaki K, Kondo K, Bando Y, Tangoku A. [Surgically treated pleomorphic carcinoma of the lung]. Kyobu Geka 2009; 62:202-206. [PMID: 19280950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We experienced 3 resected cases of pleomorphic carcinoma of the lung. Each cases were 74-year-old man (case 1), 74-year-old woman (case 2) and 69-year-old man (case 3). Two patients (case 1 and 2) were histologically diagnosed as pleomorphic carcinoma composed of spindle cell carcinoma with giant cell carcinoma. One patient (case 3) was similarly diagnosed as pleomorphic carcinoma composed of spindle cell carcinoma with adenocarcinoma and squamous cell carcinoma. Although lymph nodes metastasis were not recognized in all patients, invasion to vessels were recognized in 2 patients (case 1 and 3). In one patient (case 1), recurrence was recognized at contralateral side 1 month after surgery and he died of other disease 2 months after surgery. The other 2 patients were alive without recurrence 24 and 5 months after surgery. Recently it is reported that recurrence is recognized at early phase after surgery and prognosis is poor in a case with vessel invasions in spite of pathological NO state. Since one patient (case 3) had nonmetastatic lymph nodes with vessel invasions, careful observation is considered to be necessary.
Collapse
Affiliation(s)
- H Toba
- Department of Thoracic and Endocrine Surgery and Oncology, the University of Tokushima Graduate School, Tokushima, Japan
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Bando Y, Noguchi K, Kobayashi H, Yoshida N, Ishikawa I, Izumi Y. Cyclooxygenase-2-derived prostaglandin E2 is involved in vascular endothelial growth factor production in interleukin-1alpha-stimulated human periodontal ligament cells. J Periodontal Res 2009; 44:395-401. [PMID: 19210337 DOI: 10.1111/j.1600-0765.2008.01118.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND AND OBJECTIVE Prostaglandin E(2), which exerts its actions via EP receptors (EP1, EP2, EP3 and EP4), is a bioactive metabolite of arachidonic acid produced by cyclooxygenase-1 and/or cyclooxygenase-2. Interleukin-1alpha induces prostaglandin E(2) production via cyclooxygenase-2 in human periodontal ligament cells. Vascular endothelial growth factor is a key regulator of physiologic as well as pathologic angiogenesis and has been indicated to be involved in the pathology of periodontal diseases. In the present study, we investigated whether interleukin-1alpha induced vascular endothelial growth factor production in human periodontal ligament cells and whether cyclooxygenase-2-derived prostaglandin E(2) regulated interleukin-1alpha-induced vascular endothelial growth factor production. MATERIAL AND METHODS Human periodontal ligament cells were obtained from extracted teeth of periodontally healthy subjects. After pre-incubation with a nonselective cyclooxygenase-1/2 inhibitor, indomethacin or a selective cyclooxygenase-2 inhibitor (NS-398), periodontal ligament cells were treated with or without interleukin-1alpha, prostaglandin E(2), various EP receptor agonists and dibutyryl cAMP (a cAMP analogue). The levels of vascular endothelial growth factor and prostaglandin E(2) in the culture supernatant were measured by enzyme-linked immunosorbent assay. The vascular endothelial growth factor mRNA expression was evaluated by semiquantitative reverse transcription-polymerase chain reaction. RESULTS Interleukin-1alpha induced vascular endothelial growth factor production in a dose-dependent and time-dependent manner. The interleukin-1alpha-induced vascular endothelial growth factor mRNA and protein expression was inhibited to the same extent by indomethacin and NS-398. Indomethacin and NS-398 completely inhibited interleukin-1alpha-induced prostaglandin E(2) production. Exogenous prostaglandin E(2), butaprost (an EP2 receptor agonist) and dibutyryl cAMP abolished the inhibitory effect of indomethacin on interleukin-1alpha-induced vascular endothelial growth factor production. CONCLUSION We suggest that interleukin-1alpha induced vascular endothelial growth factor production via cyclooxygenase-2-derived prostaglandin E(2) in human periodontal ligament cells. The interleukin-1alpha/prostaglandin E(2) pathway might regulate vascular endothelial growth factor production in periodontal lesions.
Collapse
Affiliation(s)
- Y Bando
- Periodontology, Department of Hard Tissue Engineering, Tokyo Medical and Dental University, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|